Back to search

Article

Impact of Sequential Therapy With Osimertinib on the Overall Survival in Patients With EGFR-mutant Non-small Cell Lung Cancer

2021-07-28

Abstract excerpt

<title>Abstract</title> <p>Purpose. We conducted a retrospective analysis of the data of patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to investigate the associations between the available treatment options and the overall survival.Methods. We retrieved the patient data from the medical charts. Patients who were diagnosed as having EGFR-mutant NSCLC and treated wi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3989b099-c93b-5cdd-8f73-870356748f1f
DOI
10.21203/rs.3.rs-747775/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact of Sequential Therapy With Osimertinib on the Overall Survival in Patients With EGFR-mutant Non-small Cell Lung CancerDOI 10.21203/rs.3.rs-747775/v1
Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.Semantic proximity
A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.Semantic proximity
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.Semantic proximity
Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression on Osimertinib.Semantic proximity
Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.Semantic proximity
The Real-Life Efficacy And Safety of Osimertinib In Pretreated Advanced Non-Small Cell Lung Cancer Patients With T790M Mutation: A Turkish Oncology Group StudySemantic proximity
Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.Semantic proximity
Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.Semantic proximity
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.Semantic proximity
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.Semantic proximity
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment.Semantic proximity
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity
Select a neighboring publication to make it the new centre.